AmreenHusainMD

Gynecologic Oncology

Genentech BioOncology Inc

Dr. Husain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
875 Blake Wilbur Dr
# Stanford
Stanford, CA 94304
Phone+1 408-885-5000

Fax+1 651-498-5618

New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 1991 - 1995
New York Medical CollegeClass of 1991
Memorial Sloan Kettering Cancer CenterFellowship, Gynecologic Oncology

PubMed

6 citations
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma.
Isabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, Haider Mahdi, Vivek Upadhyay
International Journal of Gynecological Cancer. 2023-12-04
184 citations
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiss
Journal of the National Cancer Institute. 2021-08-02
74 citations
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
Carlos Bais, Barbara Mueller, Mark F. Brady, Robert S. Mannel, Robert A. Burger
Journal of the National Cancer Institute. 2017-11-01

Journal Articles

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Amreen Husain, Sylvia Adams, Hope S Rugo, Carlos H Barrios, Eric P Winer, The New England Journal of Medicine